Skip to main content
SpringerLink
Log in

MicroRNA-215 is a potential prognostic marker for cervical cancer

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

Recently, microRNAs (miRNAs) have been shown to be involved in multiple biological pathways that can influence tumor progression and metastasis and they can serve as prognostic biomarkers in many cancers. The present study examined the prognostic significance of miR-215 in cervical cancer. The paraffin-embedded paired cervical scrape samples and tumor tissue samples from 302 patients with stage II cervical cancer were detected for the expression of miR-215 by using qRT-PCR. A miR-215-based classifier was established by using the Cox regression model. The prognostic and predictive accuracy of this classifier was determined in both the internal testing group of 138 patients, and the external independent group of 280 patients. Moreover, cervical cancer HeLa cells overexpressing miR-215 (HeLa-miR-215) were constructed and subcutaneously injected into the nude mice to examine the effect of miR-215 on tumor growth and metastasis in vivo. The results showed that the expression level of miR-215 was significantly higher in cervical cancer tissues than in paired normal tissues (P<0.0001). When patients were classified into high- and low-risk cancer progression groups according to miR-215 level, the 5-year disease-free survival in high- and low-risk groups were 43% (95% CI: 32.1–51.6) and 67% (95% CI: 48.6–77.3) (hazard ratio [HR] 2.02, 95% CI: 1.16–3.52; P=0.013) respectively. Moreover, the expression level of miR-215 was negatively associated with survival rate in patients at TNM stage T3 (HR: 3.317; 95% CI: 1.18–5.14, P=0.017) and TNM stage T4 (HR: 3.48; 95% CI: 1.49–4.45, P=0.008). Tumor volume in nude mice injected with HeLa-miR-215 cells was significantly larger than that in mice injected with control HeLa cells. It was concluded that the expression level of miR-215 is associated with cervical tumor progression and worse survival rate, suggesting that it may serve as a potential prognostic marker to identify patients at higher risk of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schiffman M, Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med, 2013,369(24):2324–2331

    Article  PubMed  CAS  Google Scholar 

  2. Zhang Q, Liu D, Hang C, et al. Primary screening for breast diseases among 17618 women in Wufeng area, a region with high incidence of cervical cancer in China. J Huazhong Univ Sci Technol [Med Sci], 2012,32(2):252–256

    Article  Google Scholar 

  3. Pareja R, Rendon GJ, Sanz-Lomana CM, et al. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy—a systematic literature review. Gynecol Oncol, 2013,131(1):77–82

    Article  PubMed  Google Scholar 

  4. Chmura A, Wojcieszek A, Mrochem J, et al. Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma. Ginekol Pol, 2009,80(5):361–366

    PubMed  Google Scholar 

  5. Volgger B, Aspisirengil C, Genser-Krimbacher E, et al. Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix. Cancer Lett, 2008,262(2):183–189

    Article  PubMed  CAS  Google Scholar 

  6. Zhang Y, Wang X, Ma L, et al. Clinical significance of hTERC gene amplification detection by FISH in the screening of cervical lesions. J Huazhong Univ Sci Technol [Med Sci], 2009,29(3):368–371

    Article  CAS  Google Scholar 

  7. Yang MH, Yu J, Chen N, et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS One, 2013,8(12):e85353

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  8. Ben Gacem R, Ben Abdelkrim O, Ziadi S, et al. Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol, 2013, [PMID:24375250]

    Google Scholar 

  9. Gilabert-Estelles J, Braza-Boils A, Ramon LA, et al. Role of microRNAs in gynecological pathology. Curr Med Chem, 2012,19(15):2406–2413

    Article  PubMed  CAS  Google Scholar 

  10. Zhang X, Mao H, Lv Z. MicroRNA role in thyroid cancer pathogenesis. Front Biosci (Landmark Ed). 2013,18:734–739

    Article  CAS  Google Scholar 

  11. Huang Y, Shen XJ, Zou Q, et al. Biological functions of microRNAs: a review. J Physiol Biochem, 2011, 67(1):129–139

    Article  PubMed  CAS  Google Scholar 

  12. Yang C, Hou C, Zhang H, et al. miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci, 2013,15(1):423–437

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  13. Pennati M, Lopergolo A, Profumo V, et al. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol, 2014,87(4):579–597

    PubMed  CAS  Google Scholar 

  14. Wang Z, Zhang H, Zhang P, et al. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol, 2013,30(2):577

    Article  PubMed  CAS  Google Scholar 

  15. Deng Y, Huang Z, Xu Y, et al. MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett, 2014,342(1):27–35

    Article  PubMed  CAS  Google Scholar 

  16. Georges SA, Biery MC, Kim SY, et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res, 2008, 68(24):10105–10112

    Article  PubMed  CAS  Google Scholar 

  17. Karaayvaz M, Zhang C, Liang S, et al. Prognostic significance of miR-205 in endometrial cancer. PLoS One, 2012,7(4):e35158

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Hinton J, Callan R, Bodine C, et al. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas. Expert Rev Mol Diagn, 2013,13(5):431–443

    Article  PubMed  CAS  Google Scholar 

  19. Cortinovis D, Monica V, Pietrantonio F, et al. MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. Curr Pharm Des, 2013, [PMID:24138721]

    Google Scholar 

  20. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta biochimica Polonica, 2012,59(4):467–474

    PubMed  CAS  Google Scholar 

  21. Khella HW, Bakhet M, Allo G, et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis, 2013,34(10):2231–2239

    Article  PubMed  CAS  Google Scholar 

  22. Boni V, Bitarte N, Cristobal I, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther, 2010,9(8):2265–2275

    Article  PubMed  CAS  Google Scholar 

  23. Braun CJ, Zhang X, Savelyeva I, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res, 2008,68(24):10094–10104

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  24. Wijnhoven BP, Hussey DJ, Watson DI, et al. MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg, 2010,97(6):853–861

    Article  PubMed  CAS  Google Scholar 

  25. Karaayvaz M, Pal T, Song B, et al. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer, 2011,10(4):340–347

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Deng Y, Huang Z, Xu Y, et al. MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett, 2014,342(1):27–35

    Article  PubMed  CAS  Google Scholar 

  27. Walter BA, Valera VA, Pinto PA, et al. Comprehensive microRNA profiling of prostate cancer. J Cancer, 2013,4(5):350–357

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  28. Marisa L, de Reynies A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med, 2013,10(5):e1001453

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  29. Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer, 2011,10(2):73–80

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  30. Zhang JX, Song W, Chen ZH, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol, 2013,14(13):1295–1306

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, China

    Hua Liang  (梁 华), Ruo-yu Luo  (洛若愚) & Fu-jin Shen  (申复进)

  2. Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060, China

    Yan Li  (李 艳)

Authors
  1. Hua Liang  (梁 华)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Li  (李 艳)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruo-yu Luo  (洛若愚)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fu-jin Shen  (申复进)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan Li  (李 艳).

Additional information

This project was supported by the National Natural Science Foundation of China (No. 81000771).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, H., Li, Y., Luo, Ry. et al. MicroRNA-215 is a potential prognostic marker for cervical cancer. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 34, 207–212 (2014). https://doi.org/10.1007/s11596-014-1260-x

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-014-1260-x

Key words

Search

Navigation